Nutex Health Lawsuit: Securities Fraud and Shareholder Derivative Suit

The Nutex Health lawsuit landscape centers on two investor cases filed in Houston federal court in 2025: a securities fraud class action and a shareholder derivative suit, both alleging that the micro-hospital operator’s executives misled the market about a revenue surge that depended on a billing partner’s aggressive — and, according to insurers, fraudulent — use of the No Surprises Act arbitration process. Separately, four Blue Cross Blue Shield insurers have sued Nutex’s billing partner HaloMD, though Nutex itself is not named as a defendant in those cases.

What Triggered the Lawsuits

On July 22, 2025, activist short-seller Blue Orca Capital published a report accusing Nutex and HaloMD of exploiting the federal Independent Dispute Resolution (IDR) system to generate unsustainable revenue.1Yahoo Finance. Blue Orca Capital Takes Short Position in Nutex Health The report warned that much of Nutex’s recognized revenue “may be uncollectible” and predicted the stock would “return to penny stock status.”2PR Newswire. Nutex Health Shares Fall Amid Critical Blue Orca Report Shares dropped $11.18 that day, closing at $100.01.3Levi & Korsinsky. Bhagavan v. Nutex Health, Complaint

Three weeks later, on August 14, 2025, Nutex announced it would delay its quarterly report, citing the need for “non-cash accounting adjustments.” The stock fell another $18.22 to $92.91.3Levi & Korsinsky. Bhagavan v. Nutex Health, Complaint A week later, the company’s Audit Committee acknowledged that prior financial statements would have to be restated.4PR Newswire. Nutex Health Securities Suit Alleges Fraud and Financial Misstatements The first investor lawsuit landed the next day.

The Securities Fraud Class Action

The lead case is Bhagavan v. Nutex Health Inc., et al., Case No. 4:25-cv-03999, filed August 22, 2025, in the U.S. District Court for the Southern District of Texas.5SEC. Nutex Health Form 8-K, Securities Litigation Disclosure The proposed class covers investors who bought Nutex stock between August 8, 2024, and August 14, 2025. Alongside the company, three executives are named individually: CEO Thomas T. Vo, CFO Jon C. Bates, and President Warren Hosseinion.6Levi & Korsinsky. Nutex Health Securities Class Action Lawsuit Updates

The complaint alleges violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5 for fraud and misleading statements, plus Section 20(a) control-person liability against the executives. Plaintiffs claim leadership knew or recklessly disregarded that Nutex’s revenue growth was built on HaloMD’s allegedly fraudulent arbitration tactics, and that they repeatedly reassured investors while internal financial controls were failing.3Levi & Korsinsky. Bhagavan v. Nutex Health, Complaint

Specific statements cited include CFO Bates celebrating “29% revenue growth” in August 2024 and a “record high gross profit of 56%” in May 2025, and President Hosseinion telling investors in November 2024 that the company had “another outstanding quarter.” The complaint also points to Sarbanes-Oxley certifications Bates signed attesting that financial statements fairly presented the company’s condition.3Levi & Korsinsky. Bhagavan v. Nutex Health, Complaint

On November 19, 2025, Judge Charles Eskridge appointed two co-lead plaintiffs and designated Levi & Korsinsky, LLP and Pomerantz LLP as co-lead counsel.7Levi & Korsinsky. Lead Plaintiffs Appointed in Nutex Health Shareholder Litigation As of early 2026, no motions to dismiss, settlement discussions, or trial date had been reported.

The Shareholder Derivative Suit

A separate investor case was filed September 8, 2025, by shareholder Juan Camilo Jimenez in the same federal court, Case No. 4:25-cv-04253.8Sahm Capital. Derivative Lawsuit Filed Against Nutex Health Executives and Board This is a derivative action, meaning it is brought in the company’s own name against its leadership for allegedly harming Nutex itself. Recoveries would go to the company, not directly to individual shareholders — a key difference from the class action.

The suit names the CEO, CFO, President, and most of the board as defendants. The claims include breach of fiduciary duty, gross mismanagement, abuse of control, unjust enrichment, waste of corporate assets, and violations of the Securities Exchange Act. The complaint alleges that leadership publicly touted arbitration-driven growth and improved internal controls while concealing that the results depended on what the suit calls HaloMD’s “fragile and opaque” methods, including mass submissions, ineligible claim batching, and misrepresentations to arbitrators.9Healthcare Law Brief. Shareholder Derivative Lawsuit Challenging Provider Use of No Surprises Act IDR Process The derivative suit also remained in early stages as of late 2025.

The Arbitration Strategy at the Heart of the Claims

Both investor cases hinge on how Nutex generated the revenue growth that drove its stock from near-delisting to triple-digit share prices. The federal No Surprises Act, effective January 2022, created an Independent Dispute Resolution process — essentially binding arbitration — for payment fights between out-of-network providers and insurers. On July 1, 2024, Nutex hired HaloMD to run its out-of-network claims through this process.10SEC. Nutex Health Form 8-K Filing

Within months, Nutex was funneling 60 to 70 percent of its monthly billable visits into IDR arbitrations and reporting a win rate above 80 percent.11Nutex Health. Nutex Health Issues No Surprises Act Arbitration Update For full-year 2024, the company attributed roughly $169.7 million in additional revenue — over 70 percent of its year-over-year growth — to IDR recoveries.12Nutex Health. Nutex Health Q4 2024 Earnings Report Revenue per hospital visit reportedly tripled. In May 2024, Nutex had been under a Nasdaq delisting notice for failing to maintain a $1.00 share price.13Nutex Health. Nutex Health Announces Nasdaq Delisting Notification and Stay Pending Ongoing Appeal The arbitration boom reversed that trajectory.

The investor plaintiffs allege this growth was neither durable nor properly disclosed. Only about 1 percent of Nutex’s reimbursement comes from Medicare or Medicaid; the company relies on commercial insurance, frequently as an out-of-network provider, which is precisely the position IDR was designed to govern.

The Financial Restatements

Nutex’s August 2025 restatement was the second major event feeding the class action. The Audit Committee concluded that the company had improperly classified certain stock-based compensation obligations tied to hospitals under construction as equity when they should have been liabilities.4PR Newswire. Nutex Health Securities Suit Alleges Fraud and Financial Misstatements Amended annual (10-K/A) and quarterly (10-Q/A) reports followed.

For fiscal 2024, the restatement reclassified $16.4 million from equity to liabilities, increasing total liabilities by $13.4 million (about 3 percent) and reducing equity by the same amount, with roughly a $0.5 million decrease in net income.14Nutex Health. Nutex Health Reports Restated 2024 Financial Results The Q1 2025 restatement involved a $20.7 million reclassification and increased reported net income by $6.6 million because of how the adjustments flowed through.15Nutex Health. Nutex Health Reports Restated First Quarter 2025 Financial Results Nutex called the adjustments non-cash and immaterial to operations, but acknowledged that a material weakness in internal controls first identified for 2024 remained unresolved through at least Q1 2025.16Stock Titan. Nutex Health Amended Quarterly Earnings Report That unresolved weakness is a central allegation in the class action.

Insurer Lawsuits Against HaloMD, Not Nutex

Nutex is not a defendant in the insurer lawsuits that first drew public attention to the arbitration scheme. Those cases target HaloMD and its founders, Alla and Scott LaRoque. Four Blue Cross Blue Shield-affiliated insurers have sued:

Nutex has emphasized that it operates no facilities in the jurisdictions where HaloMD was sued.10SEC. Nutex Health Form 8-K Filing The BCBS Texas complaint did cite Nutex by name as a provider benefiting from HaloMD’s alleged conduct.19Capybara Research. Nutex Health Part Two HaloMD called the suits “meritless” and argued the No Surprises Act bars courts from second-guessing IDR outcomes.

So far that argument has mostly held. By spring 2026, four federal courts had dismissed insurer challenges to IDR awards, including the BCBS Texas and Anthem California cases. The Texas judge ruled that courts lack authority to relitigate IDR decisions; the California judge found Anthem had not shown sufficient evidence of system misuse.20Healthcare Dive. BCBS Texas HaloMD Surprise Billing Lawsuit Dismissed17Healthcare Finance News. Elevance Subsidiary No Surprises Act Lawsuit Dismissed BCBS Texas has appealed. The Georgia and Ohio cases remain pending. These rulings do not resolve the investor cases, which turn on disclosure, not on reopening the arbitration awards themselves.

Where the Cases Stand

As of mid-2026, both the securities class action and the derivative suit remain in their early phases, with no dispositive motions or settlement discussions publicly reported. Lead plaintiffs and lead counsel have been appointed in the class action; the derivative case is still developing. Nutex continues to operate its network of roughly 20 micro-hospitals across eight states and has said it plans to open five new facilities per year.21SEC. Nutex Health Annual Report, Form 10-K The core unresolved question is whether the arbitration-driven revenue model that lifted the stock can hold up under the combined weight of the investor suits, the acknowledged internal control weakness, and the continuing litigation over HaloMD’s methods.